Skip to main content
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. — Investor Relations & Filings

Ticker · DSGN ISIN · US25056L1035 US Manufacturing
Open in API
Filings indexed 242 across all filing types
Latest filing 2021-03-24 Regulatory Filings
Country US United States of America
Listing US DSGN

About Design Therapeutics, Inc.

https://www.designtx.com/

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a new class of small molecule therapies for genetic diseases. The company's proprietary GeneTAC® (Gene Targeted Chimera) platform is used to design therapeutic candidates that target the underlying cause of genetic disorders. These molecules are engineered to modulate gene expression—either increasing or decreasing it as needed—without requiring gene editing. The company's initial focus is on monogenic diseases driven by nucleotide repeat expansions, with programs targeting conditions such as Friedreich ataxia, myotonic dystrophy, Fuchs endothelial corneal dystrophy, and Huntington’s disease. The company aims to develop functional cures for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-03-24 English
Regulatory Filings 2021
Regulatory Filings
2021-03-24 English
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC for registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It describes the registration of common stock on The Nasdaq Stock Market LLC. The document is a regulatory filing related to securities registration, not a financial report, earnings release, or other specific report types. It is a formal regulatory announcement of securities registration, fitting best under Regulatory Filings (RNS). The document length is 3212 characters, which is short and consistent with a regulatory filing rather than a full report.
2021-03-23 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC regarding a Registration Statement on Form S-1 for Design Therapeutics, Inc. It requests acceleration of the effective date of the Form S-1 registration statement and mentions distribution of the Preliminary Prospectus. The letter is signed by representatives of underwriters. The content is related to the process of securities registration and underwriting, not a financial report or earnings release. It is a regulatory communication related to capital raising but does not itself constitute a capital/financing update report or a prospectus. Given the nature of the document as a regulatory filing related to securities registration and compliance, and its short length (2119 characters), it fits best under Regulatory Filings (RNS).
2021-03-23 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from Design Therapeutics, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references the Registration Statement and the Securities Act of 1933, indicating it relates to a securities offering process. The document is short (2018 characters) and is a correspondence letter rather than a report or financial statement. It does not contain financial data or detailed report content but is an official communication about the registration process. Therefore, it is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and correspondence that do not fit other categories.
2021-03-23 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel responding to comments from the SEC staff regarding a Registration Statement on Form S-1 filed by Design Therapeutics, Inc. It discusses amendments to the Registration Statement and filing of exhibits. The document is correspondence related to a regulatory filing process, specifically an S-1 registration statement amendment, and does not contain financial statements or detailed financial data itself. It is not an annual report, earnings release, or any other financial report type. It is also not a report publication announcement since it is a detailed response letter. Given the nature of the document as a regulatory correspondence and response to SEC comments, the appropriate classification is Regulatory Filings (RNS). The document length is under 5,000 characters and is a letter format, consistent with RNS filings.
2021-03-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.